[go: up one dir, main page]

DK1438340T3 - Antistoffer mod KDR, deres fremstilling og anvendelser - Google Patents

Antistoffer mod KDR, deres fremstilling og anvendelser

Info

Publication number
DK1438340T3
DK1438340T3 DK02800666.6T DK02800666T DK1438340T3 DK 1438340 T3 DK1438340 T3 DK 1438340T3 DK 02800666 T DK02800666 T DK 02800666T DK 1438340 T3 DK1438340 T3 DK 1438340T3
Authority
DK
Denmark
Prior art keywords
disclosed
kdr
preparation
cdr
antibody
Prior art date
Application number
DK02800666.6T
Other languages
English (en)
Inventor
Andrew George Popplewell
Simon Peter Tickle
Karen Zinkewich-Peotti
Robert Kendall Morrison
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of DK1438340T3 publication Critical patent/DK1438340T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
DK02800666.6T 2001-10-10 2002-10-10 Antistoffer mod KDR, deres fremstilling og anvendelser DK1438340T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124317.9A GB0124317D0 (en) 2001-10-10 2001-10-10 Biological products
PCT/GB2002/004619 WO2003031475A2 (en) 2001-10-10 2002-10-10 Antibodies against kdr, their production and uses

Publications (1)

Publication Number Publication Date
DK1438340T3 true DK1438340T3 (da) 2010-11-22

Family

ID=9923562

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02800666.6T DK1438340T3 (da) 2001-10-10 2002-10-10 Antistoffer mod KDR, deres fremstilling og anvendelser

Country Status (24)

Country Link
US (2) US7452976B2 (da)
EP (1) EP1438340B1 (da)
JP (2) JP4323312B2 (da)
KR (2) KR101018908B1 (da)
CN (1) CN1568331A (da)
AT (1) ATE482234T1 (da)
AU (1) AU2002334135B8 (da)
BR (1) BR0212756A (da)
CA (1) CA2458464A1 (da)
CO (1) CO5580838A2 (da)
DE (1) DE60237778D1 (da)
DK (1) DK1438340T3 (da)
EA (1) EA010970B1 (da)
ES (1) ES2351208T3 (da)
GB (1) GB0124317D0 (da)
HU (1) HUP0401618A3 (da)
IL (1) IL160849A0 (da)
IS (1) IS7173A (da)
MX (1) MXPA04003274A (da)
NO (1) NO20040987L (da)
NZ (1) NZ532758A (da)
PL (1) PL208848B1 (da)
WO (1) WO2003031475A2 (da)
ZA (1) ZA200401910B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
MXPA06000798A (es) * 2003-07-22 2006-04-07 Schering Ag Anticuerpos de rg1 y usos de los mismos.
GB0329825D0 (en) * 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
EA014226B1 (ru) 2004-07-26 2010-10-29 Байоджен Айдек Ма Инк. Антитела к cd154, их фрагменты и способы применения антител и фрагментов
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
ES2558338T3 (es) * 2005-03-25 2016-02-03 National Research Council Of Canada Método para aislamiento de polipéptidos solubles
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
TWI551607B (zh) 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
PL2125894T3 (pl) 2007-03-22 2019-08-30 Biogen Ma Inc. Białka wiążące, w tym przeciwciała, pochodne przeciwciał i fragmenty przeciwciał, które swoiście wiążą się z CD154 i ich zastosowania
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
CA2701793C (en) 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
AU2010216152B2 (en) * 2009-02-17 2015-05-14 Ucb Biopharma Sprl Antibody molecules having specificity for human OX40
CN101531718B (zh) * 2009-04-22 2011-11-02 中国人民解放军南京军区军事医学研究所 抗VEGFR-2抗体嵌合Fab抗体片段及其制备方法、应用
EP2480661A1 (en) 2009-09-24 2012-08-01 UCB Pharma, S.A. Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
MX348738B (es) 2011-07-13 2017-06-27 Ucb Pharma Sa Cepa huesped bacteriana que expresa dsbc recombinante.
BR112014010774A2 (pt) 2011-11-02 2017-06-13 Apexigen Inc anticorpos anti-kdr e métodos de uso
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
EP2818480B1 (en) 2012-02-24 2020-08-26 Alteogen Inc. Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
JP6144771B2 (ja) 2012-11-21 2017-06-07 ファームアブシン インコーポレイテッド Ｖｅｇｆｒ−２とｄｌｌ４を標的とする二重標的抗体及びこれを含む薬学的組成物
WO2018195008A1 (en) * 2017-04-21 2018-10-25 Mellitus, Llc Methods and antibodies for diabetes-related applications
US12285484B2 (en) 2018-09-19 2025-04-29 Absci Corporation Cancer associated antibody compositions and methods of use
JP2022514615A (ja) * 2018-12-20 2022-02-14 アルバート アインシュタイン カレッジ オブ メディスン ヒト免疫チェックポイントＣＥＡＣＡＭ１（ＣＤ６６ａ）に対するアンタゴニスト抗体及びその製剤、キット並びに使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8903022D0 (en) 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
CN1173991C (zh) 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
DE19638745C2 (de) * 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
DE69838334T2 (de) 1997-06-18 2008-06-12 Merck & Co., Inc. (A New Jersey Corp.) Kdr, ein menschlicher tyrosin kinase rezeptor
WO1999059636A1 (en) * 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
CA2361553A1 (en) 1999-01-29 2000-08-03 Zhenping Zhu Antibodies specific to kdr and uses thereof

Also Published As

Publication number Publication date
JP2005516590A (ja) 2005-06-09
ATE482234T1 (de) 2010-10-15
KR20040097983A (ko) 2004-11-18
DE60237778D1 (de) 2010-11-04
PL208848B1 (pl) 2011-06-30
BR0212756A (pt) 2004-11-16
HUP0401618A2 (hu) 2004-11-29
NO20040987L (no) 2004-05-10
US7842787B2 (en) 2010-11-30
CA2458464A1 (en) 2003-04-17
JP2009108086A (ja) 2009-05-21
EP1438340B1 (en) 2010-09-22
AU2002334135B2 (en) 2009-01-08
EA200400519A1 (ru) 2004-12-30
IL160849A0 (en) 2004-08-31
MXPA04003274A (es) 2004-07-08
WO2003031475A8 (en) 2004-10-14
WO2003031475A2 (en) 2003-04-17
PL370344A1 (en) 2005-05-16
US7452976B2 (en) 2008-11-18
ZA200401910B (en) 2005-03-09
AU2002334135B8 (en) 2009-01-29
KR101018908B1 (ko) 2011-03-02
US20050181448A1 (en) 2005-08-18
EA010970B1 (ru) 2008-12-30
EP1438340A2 (en) 2004-07-21
ES2351208T3 (es) 2011-02-01
US20090269840A1 (en) 2009-10-29
HUP0401618A3 (en) 2012-03-28
CO5580838A2 (es) 2005-11-30
NZ532758A (en) 2008-04-30
CN1568331A (zh) 2005-01-19
KR20070116110A (ko) 2007-12-06
WO2003031475A3 (en) 2004-03-25
IS7173A (is) 2004-03-05
GB0124317D0 (en) 2001-11-28
JP4323312B2 (ja) 2009-09-02

Similar Documents

Publication Publication Date Title
DK1438340T3 (da) Antistoffer mod KDR, deres fremstilling og anvendelser
LTPA2017043I1 (lt) Antikūnai, specifiški žmogaus CD22, ir jų terapinis bei diagnostinis panaudojimas
AP2092A (en) Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof.
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE398676T2 (de) Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins